
January to March 2025
| Drug Name | Government Contribution Dollars | Prescriptions |
|---|---|---|
| PEMBROLIZUMAB | $167,992,754 | 19,763 |
| ELEXACAFTOR + TEZACAFTOR + IVACAFTOR (&) IVACAFTOR | $153,093,856 | 7,160 |
| USTEKINUMAB | $134,958,659 | 19,168 |
| AFLIBERCEPT | $121,394,489 | 123,090 |
| DUPILUMAB | $119,401,901 | 69,649 |
| NIVOLUMAB | $100,530,654 | 13,994 |
| SEMAGLUTIDE | $81,034,835 | 693,007 |
| DENOSUMAB | $74,587,900 | 298,414 |
| UPADACITINIB | $71,124,290 | 48,916 |
| APIXABAN | $61,942,638 | 1,023,054 |
| OCRELIZUMAB | $61,391,140 | 3,747 |
| ADALIMUMAB | $56,541,296 | 98,053 |
| Drug Name | Government Contribution Dollars | Prescriptions |
|---|---|---|
| ROSUVASTATIN | $23,493,078 | 3,852,643 |
| ATORVASTATIN | $17,979,604 | 2,674,655 |
| PANTOPRAZOLE | $16,291,391 | 2,576,070 |
| ESOMEPRAZOLE | $13,454,340 | 1,842,301 |
| ESCITALOPRAM | $5,848,680 | 1,574,315 |
| PERINDOPRIL | $9,044,480 | 1,500,179 |
| SERTRALINE | $6,034,849 | 1,497,748 |
| METFORMIN | $8,552,274 | 1,388,411 |
| CEFALEXIN | $5,841,651 | 1,277,660 |
| AMLODIPINE | $6,532,074 | 1,088,516 |
| APIXABAN | $61,942,638 | 1,023,054 |
| TELMISARTAN | $5,564,606 | 980,015 |
| Contributor | Contribution Dollars |
|---|---|
| Australian Government | $4,560,981,132 |
| Patients | $988,380,908 |